A judge has said that Johnson & Johnson is supposed to pay $8 billion in the case of male breast growth linked to Risperdal. Philadelphia judge said that Johnson & Johnson must pay $8 billion in damages to a man who already won $680,000 over his claims that the company was unable to warn young men using its antipsychotic drug Risperdal are capable to grow breasts, as per the report.
The judge’s decision in favor of Nicholas Murray came in the first case in which a Pennsylvania judge had been able to consider awarding punitive damages in one of many Risperdal cases pending in the judiciary. The concerns have accused that J&J failed to warn of the risk of gynecomastia, the development of enlarged breasts in males, associated with Risperdal. According to the report, J&J stated the most recent award was “grossly disproportionate with the initial compensatory award in this case, and the company is confident it will be overturned”. It further said that the judge in the case was not been made to hear the evidence of Risperdal’s benefits. In 2015 Murray was awarded $1.75 million after finding J&J was lazy in warning of the risk of gynecomastia. Murray accused in his lawsuit that he developed breasts after his doctors began prescribing him Risperdal in 2003, the report went on. The state requests court to sustain the verdict on February 2018, but reduced it to $680,000.“This jury, as have other juries in other litigations, once again imposed punitive damages on a corporation that valued profits over safety and profits over patients,” stated Tom Kline and Jason Itkin, Murray’s lawyers in a combined statement. “Johnson & Johnson and Janssen chose billions over children.”
The US Food and Drug Administration approved the drug in 1993 for dealing with schizophrenia and episodes of bipolar mania in adults.